Amersham looks to diagnostics with Motorola deal:
This article was originally published in Clinica
Executive Summary
UK company Amersham has bought Motorola Life Science's CodeLink pre-arrayed slides business in a $20m deal. The high-growth, $500m microarray market is mainly focused on the study of gene expression, but there is a significant opportunity to expand this into applications for clinical diagnostics, Amersham believes. The acquisition also builds on Amersham Biosciences' position in the self-spotted array market.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.